CD28 serves as the receptor for CD80 (B7.1) and CD86 (B7.2). When antigen-presenting cells (APCs) are activated by Toll-like receptor ligands, CD80 expression is upregulated, while CD86 expression ...

There are currently seven known members of this family of ligands. The most well-known are B7-1 (CD80) and B7-2 (CD86), which interact with CD28 and CTLA-4 to regulate T cell signaling.

The CD28 signal is diminished in cancer because tumor cells do not typically express CD28 ligands (i.e., CD80 and CD86), which leads to potentially compromised activity of CD3 T cell engagers or ...

PD-1 is now recognized to effect much of its benefit by disinhibiting CD28 signaling – a mechanism expected to require intra-tumoral engagement of CD28 by its ligands CD80/CD86. Davoceticept (ALPN-202 ...

Role of CTLA-4 CTLA-4 is a CD28 homologue that binds to CD80/CD86 (B7 ligands) with high avidity and affinity to inhibit T-cell function. 1,3 It is expressed on the surface of activated CD4-positive ...

Engagement of CD28 on CD4+ T cells with CD80/CD86 (B7.1/B7.2) on antigen presenting cells (APCs) is required for GC formation, but recent data suggest a limited role for B cell-intrinsic CD80/CD86 in ...

Expression of CD80 and CD86 was strongly dependent upon provision of CD28 costimulation as ligands were not expressed following TCR stimulation alone. Furthermore, we observed that CD80 + T cells ...

Taken together, our data suggest that CD86 is the dominant costimulatory ligand for Treg homeostasis, despite its lower affinity for CD28, because CD80-CD28 interactions are selectively impaired by ...

Hypothesis: We hypothesized that the blockade of CD28-CD80/CD86 costimulatory pathway by anti-CD80/CD86 monoclonal antibodies (mAbs) induces T cell anergy in vivo and suppresses immune rejection in ...